A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Acute coronary syndromes; Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Acronyms ODYSSEY-Outcomes
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Mar 2018 Results (n=730) presented in the Sanofi Media Release.
    • 10 Mar 2018 Results (n=730) presented in the Regeneron Pharmaceuticals Media Release
    • 10 Mar 2018 According to a Regeneron Pharmaceuticals media release, results of this study will be present at the American College of Cardiology's 67th Annual Scientific Session.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top